Drug Profile
Tegoprazan - HK inno.N/RaQualia Pharma
Alternative Names: BLI-5100; CJ-12420; IN-A001; K-CAB; LXI-15028; RQ-00000004; RQ-4; Tegoprazan Tablet 12.5 mgLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer CJ Cheiljedang Corp.; HK inno.N; RaQualia Pharma; Sebela Pharmaceuticals; Shandong Luoxin Pharmaceutical
- Class Amides; Anti-inflammatories; Antibacterials; Antiulcers; Benzimidazoles; Benzopyrans; Fluorobenzenes; Small molecules
- Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erosive oesophagitis; Gastro-oesophageal reflux
- Phase III Duodenal ulcer; Gastric ulcer; Helicobacter infections; Peptic ulcer
Most Recent Events
- 17 Apr 2024 Phase I development is ongoing in Japan for Gastro-oesophageal-reflux (PO) (RaQualia Pharma pipeline, April 2024)
- 17 Apr 2024 Launched for Gastro-oesophageal reflux in Mexico (PO), prior to April 2024 (RaQualia Pharma pipeline, April 2024)
- 17 Apr 2024 Launched for Gastro-oesophageal reflux in Singapore, Peru , Indonesia (PO), prior to April 2024 (RaQualia Pharma pipeline, April 2024)